PT-141 Single vial · Melanocortin Research
Strength
Volume pricing
Any mix of Express vials counts. Not combined with discount codes.
Add 1 more to unlock 5% off
Your basket is empty
With this one in, 1 vial more of anything and the whole basket is 5% off.
For laboratory research use only. Not for human or veterinary use.
Buying at volume? PT-141 factory direct
About PT-141+
About PT-141
PT-141 (bremelanotide) is a synthetic cyclic seven-amino-acid peptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), developed by Palatin Technologies from melanotan II. Small early trials were run in men with erectile dysfunction. In the US it was approved in 2019, as for premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or difficulty between partners and is not due to another medical or mental health condition, relationship problems or a medicine. It is not approved for men or for women after the menopause, and it is not licensed in the UK or EU. The approval rests mainly on two identical 24-week randomised, placebo-controlled phase 3 trials (RECONNECT) that enrolled 1,267 women, almost all at US sites (Kingsberg et al., Obstet Gynecol 2019). Both trials were funded by the developers. Nausea, flushing and headache were more common than with placebo. The US label states that how it acts in HSDD is unknown, and it warns of a short-lived rise in blood pressure and of darker patches of skin in a small number of patients. These research materials are not the licensed medicine. Supplied for laboratory research use only.
Mechanism
Bremelanotide activates several melanocortin receptors. The US label lists its potency order as MC1R, then MC4R, MC3R, MC5R and MC2R, with MC1R and MC4R the most relevant at the levels reached in patients. MC4R is found in the brain and spinal cord, in pathways that mouse and rat studies link to sexual behaviour (Van der Ploeg et al., 2002), while MC1R is the receptor on pigment cells that drives melanin production. The label states that the way it acts in hypoactive sexual desire disorder is unknown.
Storage and handling
- Sealed and lyophilised, store at 2 to 8°C away from light and moisture. Minus 20°C for longer.
- Once reconstituted, keep refrigerated and avoid repeated freeze and thaw cycles.
- Bacteriostatic water is the usual diluent. The volume added sets the concentration in mg per mL.
- Vials carry a batch number for your laboratory records. Recent independent lab results are published in our COA Library.
FAQs
Can I order a single vial of PT-141 without a minimum order?+
Yes. The single-vial range exists precisely so a laboratory can take one vial of PT-141 rather than a full Factory Direct kit of 10. There is no minimum order quantity on this format.
How quickly does a PT-141 single vial ship in the UK?+
Single vials are held in our UK facility and dispatched within 24 hours of a cleared payment on working days, on a tracked UK service. Orders placed at the weekend go out on the next working day.
How does the single vial differ from the factory-direct box?+
The compound and the manufacturing source are the same. The Factory Direct kit is a 10-vial pack and a lower per-vial cost, while the single vial is one vial from UK stock for small-scale or pilot work.
What purity is stated for PT-141?+
99%+ manufacturer-stated purity. Buyers are encouraged to run independent third-party verification, and our testing directory lists laboratories that perform it.
Is this PT-141 vial for human use?+
No. Every Peptx product, including the single-vial range, is supplied strictly for laboratory research. It is not for human consumption, diagnosis, treatment or any clinical use.
What is PT-141?+
PT-141, also called bremelanotide, is a synthetic cyclic peptide analogue of alpha-MSH, developed from melanotan II. In the US it is approved as a medicine for a specific group of premenopausal women with hypoactive sexual desire disorder, and the research material supplied here is not that medicine. It is supplied for laboratory research use only.
How does PT-141 work?+
It activates several melanocortin receptors, mainly MC1R and MC4R at the levels reached in patients. MC4R sits in brain and spinal cord pathways that animal studies link to sexual behaviour, but the US label states that how it acts in hypoactive sexual desire disorder is unknown.
What did the human trials find?+
Two 24-week randomised placebo-controlled phase 3 trials in 1,267 premenopausal women with hypoactive sexual desire disorder measured changes in desire and distress scores, and they underpin the 2019 US approval (Kingsberg et al., 2019). Nausea, flushing and headache were the most common side effects, and the label also warns of a brief rise in blood pressure. It is not approved for men or for women after the menopause.
How is PT-141 stored?+
Store the freeze-dried powder sealed, cold and away from light, following standard laboratory peptide storage procedures. See the product specifications for detailed storage requirements.
Other single vials in Melanocortin Research
Strictly for laboratory research. Not for human consumption, diagnosis or treatment.